Systemic Mastocytosis Treatment with Midostaurin: [ 18 F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome.

We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent 18 F-Fluorodeoxyglucose ([ 18 F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Post-therapeutic [ 18 F]FDG PET/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient's symptoms and decrease in serum tryptase level. [ 18 F]FDG PET/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis.